Genialis KrasID

Genialis has launched krasID, a biomarker algorithm that can predict patient response to KRAS inhibitors across tissue histology and mutation type. It uses machine learning to model biological processes from the gene expression of patient-derived tumors and has been validated on data from non-small cell lung cancer patients as well as from preclinical and patient-derived xenograft samples for colorectal and pancreatic cancer.